Default company panoramic image

Translational Research Institute

TRI develops breakthrough medical technologies that support and enable cardiovascular therapy and treatments.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Gilbert, AZ, USA
  • Currency USD
  • Founded July 2010
  • Employees 6
  • Website

Company Summary

Translational Research Institute (TRI) was founded by stem-cell pioneer and world-renowned interventional cardiologist Dr. Nabil Dib to develop breakthrough medical technologies and devices that support and enable cardiovascular therapy and treatments. TRI advances these revolutionary technologies through basic science as well as pre-clinical and clinical trials and commercializes and disseminates them into mainstream medical practice.


  • Default avatar
    Nabil Dib, MD, MSC, FACC
    Founder and Chief Scientific Officer

    World-renowned interventional cardiologist and stem cell researcher, guiding life-changing medical concepts from bench to bedside. He is the director of cardiovascular research at Dignity Healthcare Mercy Gilbert and Chandler Regional Medical Centers and Heart Sciences Center, overseeing 20 clinical trials. He received extensive training in interventional cardiology and investigational devices during his fellowship at Harvard Medical School.

  • Default avatar
    Bret Baird

    Rich history of product development and management in market leading medical device companies. Prior to joining TRI, Bret managed vena cava filters in the Bard Peripheral Vascular division of C.R. Bard as well as angioplasty balloons. At Medtronic Neurological, he helped lead the implantable drug infusion pump product line. Bret earned an MBA at Harvard Business School and a bachelor’s degree at Brigham Young University.

  • Default avatar
    DeAnn Dana, RN
    Project Manager

    DeAnn brings years of clinical experience in interventional cardiac catheterization laboratory, interventional radiology, and other critical care areas such as ICU and ER. She is a member of American Nurses Association and American College of Cardiovascular Nursing. She is certified in NOGA 3-D mapping system, used for electromechanical imaging of the heart. She graduated from Arizona State University with degrees in nursing and English.

  • Default avatar
    Ann Campbell RN, BSN, CCRC
    Clinical Director

    Ann has had 25 years of experience in health care, including 15 years in cardiovascular research. She has held positions such as program manager in clinical research and for a biotech start-up company. Ann has been responsible for more than 30 clinical trials involving novel products, such as cardiac stem cell therapy, devices, and pharmaceuticals. Bachelor’s degree in nursing and is a certified clinical research coordinator.

  • Default avatar
    Robert Kohler
    Research & Development Manager

    Robert has more than 25 years in the medical device industry. His diverse experience encompasses product development, manufacturing, and operations. He is also currently the director of R&D at Cardiovascular Systems. He received his B.A. in mechanical engineering and business management, as well as a master’s degree in manufacturing systems, from the U. of Minnesota.

  • Default avatar
    David Brooke
    Quality Manager

    David has 20+ years experience in Regulatory Affairs and Quality Management in some of the market leading medical device companies. B.A. from Purdue University in Mechanical Engineering

  • Default avatar
    Stuart Portnoy, MD
    Regulatory Manager

    Dr. Portnoy directs TRI’s FDA regulatory strategy and agency filings, product claims and labeling, and technical considerations for market approval. Dr. Portnoy has been a medical device consultant for the past 10 years. Dr. Portnoy worked at the FDA for 8 years, including positions as branch chief of Interventional Cardiology Devices and acting deputy director of the Division of Cardiovascular Devices.


  • Default avatar
    Tobin & Connealy (Contracts); Nydegger & Associates (Intellectual Property)

Previous Investors

  • Default avatar
    William S. Lund
    Default avatar
    Gale S. Brimhall
    Default avatar
    Stacy S. Brimhall